A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia

Blood

Volumn 94, Issue 4, 1999, Pages 1192-1200

  Fenaux, Pierre ^a   Chastang, Claude ^b   Chevret, Sylvie ^b   Sanz, Miguel ^b   Dombret, Hervé ^b   Archimbaud, Eric ^b   Fey, Martin ^b   Rayon, Consuelo ^b   Huguet, Françoise ^b   Sotto, Jean Jacques ^b   Gardin, Claude ^b   Makhoul, Pascale Cony ^b   Travade, Philippe ^b   Solary, Eric ^b   Fegueux, Nathalie ^b   Bordessoule, Dominique ^b   San Miguel, Jesus ^b   Link, Harmut ^b   Desablens, Bernard ^b   Stamatoullas, Aspasia ^b   Deconinck, E ^b   Maloisel, Fréderic ^b   Castaigne, Sylvie ^b   Preudhomme, Claude ^b   Degos, Laurent ^b   more..

^a CHU Rouen BG   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING;

EID: 0033566639     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.4.1192     Document Type: Article

References (38)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick M, Sultan C: Proposals for the classification of the acute leukemias. Br J Haematol 33:451, 1976
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick M, Sultan C: A variant from of hypergranular promyelocytic leukemia (M3). Ann Intern Med 92:280, 1980
3. Larson RA, Kondo K, Vardiman JW, Butler AR, Golomb HM, Rowley JD: Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76:827, 1984
4. De The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A: The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic lerukemia encodes a functionally altered RAR. Cell 66:675, 1991
5. Kakizuka A, Miller WH, Umesono K, Warrell R, Frankel S, Dmitrovsky E, Evans R: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663, 1991
6. Tallman MS, Kwaan HC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543, 1992
7. Dombret H, Sutton L, Duarte M, Daniel MT, Leblond V, Castaigne S, Degos L: Combined therapy with all-trans retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage. Leukemia 6:1237, 1992
8. Goldberg MA, Ginsburg D, Mayer RJ, Stone RM, Maguire M, Rosenthal DS, Antin JH: Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 69:187, 1987
9. Cunningham I, Gee T, Reich L: Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood 73:1116, 1989
10. Rodighiero F, Avvisati G, Castaman G, Mandelli F: Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 11:2112, 1990
11. Fenaux P, Pollet JP, Vandenbossche L, Dupriez B, Jouet JP, Bauters F: Treatment of acute promyelocytic leukemia: A report on 70 cases. Leuk Lymphoma 4:249, 1991
12. Head D, Kopecky KJ, Willman CL, Appelbaum FR: Aggressive daunomycin (DNR) therapy improves survival in acute promyelocytic leukemia (APL), a Southwest Oncology Group (SWOG trial). Leukemia 8:s38, 1994 (suppl 2)
13. Huang M, Yu-Chen Y, Shu-Rom GC, Lu MX, Zhoa L, Gu LJ, Wang ZY: Use of all trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
14. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L: All trans-retinoic acid in promyelocytic leukemias. II. In vitro studies structure function relationship. Blood 76:1710, 1990
15. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L: All trans retinoic acid as a differentiating therapy for acute promyelocytic leukemias. I. Clinical results. Blood 76:1704, 1990
16. Warrell RP, Frankel SR, Miller W, Itri L, Andreeff M, Jabukowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid). N Engl J Med 324:1385, 1991
17. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, Wang W, Zu WY, Yao XZ, Ling BJ: A clinical and experimental study on all trans retinoic acid treated acute promyelocytic leukemia patients. Blood 78:1413, 1991
18. Degos L, Chomienne C, Daniel MT, Berger R, Dombret H, Fenaux P, Castaigne S: Treatment of first relapse in acute promyelocytic leukaemia with all trans retinoic acid. Lancet 2:1440, 1990
19. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrel R: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292, 1992
20. Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L: All trans retinoic acid treatment for patients with acute promyelocytic leukeamia. Leukemia 6:64, 1992
21. Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, Warrel RP: All trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 120:279, 1994
22. Warrell RP, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR: Treatment of accute promyelocytic leukemia with all trans-retinoic acid: An update of the New York experience. Leukemia 8:926, 1994
23. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Bordenoule D, Sadoun A, Tuberghien P, Fegueux N, Degos L: All trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia. A pilot study on 26 cases. Blood 80:2176, 1992
24. Fenaux P, Wattel E, Archimbaud E, et al: Prolonged follow up confirms that all trans retinoic acid (ATRA) followed by chemothearpy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia (APL). Blood 84:666, 1994
25. Fenaux P, Le Deley MC, Castaigne S, et al: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 82:3241, 1993
26. Fenaux P, Chastang C, Chomienne C, Degos L: Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia. Lancet 343:1033, 1994
27. Tallman MS, Andersen J, Schiffer CA, Appelbaum F, Feusner J, Ogden A, Willman C, Bloomfield C, Rowe J, Wiernik P: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021, 1997
28. Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, Dimitrovsky E: Continuous treatment with all trans RA progressively decreases plasma drug concentrations: implications for relapse and resistance in acute promyelocytic leukemia. Blood 79:299, 1992
29. Marty M, Ganem G, Fischer J, Flandrin G, Berger R, Schaison G, Degos L, Boiron M: Leucémie aiguë promyélocytaire: étude rétrospective de 119 malades traités par daunorubicine. Nouv Rev Fr Hematol 24:371, 1984
30. Kantarjian H, Keating M, Walters RS, Smith TL, Mc Credie KB, Freireich EJ: Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 59:1258, 1987
31. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
32. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 34:487, 1972
33. Peto R, Peto J: Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 135:185, 1972
34. Mandelli F, Diverlo D, Avvisati G, Barbui T, Biondi A, Lo Coco F: Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90:1014, 1997
35. Kanamaru A, Takemoto Y, Tanimoto M, Asou N, Kuriyama K, Tsubaki K, Yamada O, Matsuda S, Minato K, Ueda T, Ohno R: All trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85:1202, 1995
36. Vahdat L, Maslak P, Miller WH, Eardley A, Heller, Scheinberg DA, Warrell RP: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemias: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843, 1994
37. De Botton S, Dombret H, Sanz J, San Miguel J, Caillot D, Guerci A, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P: Incidence, clinical features and outcome of ATRA syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 92:2712, 1998
38. Delva L, Cornic M, Balitrand N, Guidez F, Miclea JM, Delmer A, Fenaux P, Castaigne S, Degos L: Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic Egger (Berne), E. Jacky. leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 82:2175, 1993